NEW DELHI (Wednesday, March 4, 2026) — Leading public health experts and clinicians have called upon Indian policymakers to reconsider the prescription-only status of 4mg nicotine gums, advocating for their re-classification as Over-The-Counter (OTC) products. The appeal, made amid a broader national debate on nicotine regulation, argues that easier access to these evidence-based cessation aids is critical for India to meet its tobacco control goals.
The Regulatory Hurdle: Schedule K and Prescription Barriers
Nicotine Replacement Therapy (NRT) gums in India are currently governed under the Drugs and Cosmetics Act, 1940. Historically, both 2mg and 4mg strengths were more accessible, but recent regulatory shifts have tightened control over the higher dose.
- Current Status: Under Schedule K of the Drugs and Cosmetics Rules, only nicotine gums up to 2mg are exempted from the requirement of a sale license and can be sold OTC.
- The 4mg Shift: Until roughly 18 months ago (late 2024), 4mg gums were widely available OTC. However, following discussions by the Drugs Technical Advisory Board (DTAB) and recommendations from the ICMR, higher doses were moved to a prescription-only category due to concerns over potential misuse.
- Expert Counter-Argument: Clinicians like Dr. Meenakshi N (Apollo Hospital, Noida) emphasize that nicotine gums are “therapeutic tools,” not “initiation products.” They argue that the 4mg dose is essential for heavy smokers (those smoking 20+ cigarettes a day) who face severe withdrawal symptoms that the 2mg dose cannot suppress.
Global Standards and WHO Endorsement
Public health advocates highlight that India’s current restrictions are out of sync with international best practices.
- WHO Essential Medicines: Nicotine gums have been on the World Health Organization’s Essential Medicines List for over three decades and were added to India’s NLEM in 2022.
- International Comparison: More than 100 countries, including the US, UK, Canada, and Australia, allow both 2mg and 4mg gums to be sold OTC without reporting significant youth initiation or misuse.
- Efficacy: Research from the Cochrane Library indicates that NRT can increase the chances of successfully quitting smoking by 50% to 70% compared to unaided attempts.
| Feature | 2mg Nicotine Gum | 4mg Nicotine Gum |
| Current India Status | OTC (Schedule K Exempt) | Prescription Required |
| Recommended For | Light to moderate smokers | Heavy/Highly dependent smokers |
| Global Access | OTC in 100+ countries | OTC in 100+ countries |
| Misuse Risk | Low (DTAB confirmed) | Low (No global evidence of abuse) |
Impact on Health Equity
Experts warn that the prescription barrier creates “health inequalities,” particularly for rural and low-income populations.
- Access Gap: In many rural areas, visiting a doctor specifically for a cessation prescription is a logistical and financial burden, leading many to simply continue smoking combustible tobacco.
- Constitutional Rights: Some legal and health experts argue that restricting access to life-saving cessation tools contradicts Article 21 (Right to Health) and the objectives of the National Tobacco Control Programme (NTCP).
“Nicotine itself is not risk-free, but the harm profile of medicinal nicotine is dramatically lower than smoking. The real danger lies in denying dependent smokers access to effective tools, especially in low-resource settings.” — Dr. Rajesh Madan, Senior Consultant Cardiologist, Max Hospital.
Sources
- Press Trust of India (PTI): “Public health experts urge evidence-based regulation of nicotine gums” (March 4, 2026)
- ETHealthworld: “Experts urge OTC availability for nicotine gum 4mg” (March 5, 2026)
- World Health Organization (WHO): “Tobacco Cessation Guidelines 2024”
- Ministry of Health and Family Welfare: “Lok Sabha Unstarred Question No. 2426 – NRT Availability” (February 13, 2026)
- Devdiscourse: “Breaking Barriers: Expanding Access to Nicotine Gums for Cessation” (March 4, 2026)
Leave a Reply